Literature DB >> 23324295

Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Yong-Hui Huang1, Wei Chen, Jia-Ping Li, Bin Chen, Jian-Yong Yang.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23324295

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


× No keyword cloud information.
  3 in total

Review 1.  Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.

Authors:  Lei Liu; Hui Chen; Mengmeng Wang; Yan Zhao; Guohong Cai; Xingshun Qi; Guohong Han
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

Review 2.  Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Lin Li; Wenzhuo Zhao; Mengmeng Wang; Jie Hu; Enxin Wang; Yan Zhao; Lei Liu
Journal:  BMC Gastroenterol       Date:  2018-09-04       Impact factor: 3.067

3.  Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies.

Authors:  Huichen Li; Songlun Li; Jie Geng; Shoujie Zhao; Kai Tan; Zhenyu Yang; Dayun Feng; Lei Liu
Journal:  Ann Transl Med       Date:  2020-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.